| Primary |
| Ill-defined Disorder |
60.0% |
| Cardiomyopathy |
40.0% |
|
|
| Secondary |
| Hypertension |
43.3% |
| Essential Hypertension |
8.2% |
| Cardiac Failure |
7.7% |
| Product Used For Unknown Indication |
6.2% |
| Hypokalaemia |
4.1% |
| Drug Use For Unknown Indication |
3.6% |
| Atrial Fibrillation |
3.1% |
| Pain |
3.1% |
| Regurgitation |
2.6% |
| Gouty Arthritis |
2.1% |
| Graft Versus Host Disease |
2.1% |
| Cardiac Disorder |
1.5% |
| Cardiovascular Event Prophylaxis |
1.5% |
| Cerebral Thrombosis |
1.5% |
| Diabetes Mellitus |
1.5% |
| Gastrooesophageal Reflux Disease |
1.5% |
| Infection |
1.5% |
| Muscle Spasms |
1.5% |
| Oedema Due To Cardiac Disease |
1.5% |
| Type 2 Diabetes Mellitus |
1.5% |
|
| Orthostatic Hypotension |
14.3% |
| Syncope |
12.5% |
| Renal Failure Acute |
10.7% |
| Renal Failure |
8.9% |
| Toxic Epidermal Necrolysis |
8.9% |
| Headache |
5.4% |
| Hypotension |
5.4% |
| Azotaemia |
3.6% |
| Duodenal Ulcer Haemorrhage |
3.6% |
| Gastrointestinal Haemorrhage |
3.6% |
| Iron Deficiency Anaemia |
3.6% |
| Urinary Tract Infection |
3.6% |
| White Blood Cell Count Increased |
3.6% |
| Diarrhoea |
1.8% |
| Fatigue |
1.8% |
| Hyponatraemia |
1.8% |
| Nausea |
1.8% |
| Pain In Extremity |
1.8% |
| Renal Disorder |
1.8% |
| Urinary Retention |
1.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
25.8% |
| Drug Use For Unknown Indication |
14.2% |
| Hypertension |
9.9% |
| Cardiac Failure |
6.2% |
| Pain |
6.1% |
| Atrial Fibrillation |
4.2% |
| Acute Myocardial Infarction |
4.0% |
| Prophylaxis |
3.6% |
| Renal Failure Chronic |
3.6% |
| Dyspnoea |
3.3% |
| Diuretic Therapy |
3.0% |
| Rheumatoid Arthritis |
2.5% |
| Hypercholesterolaemia |
2.4% |
| Diabetes Mellitus |
1.9% |
| Constipation |
1.7% |
| Depression |
1.7% |
| Osteoporosis |
1.6% |
| Thrombosis Prophylaxis |
1.6% |
| Hepatitis |
1.4% |
| Arthralgia |
1.4% |
|
| Vomiting |
11.4% |
| Renal Failure |
7.7% |
| Rhabdomyolysis |
7.3% |
| Pyrexia |
6.8% |
| Hypotension |
5.5% |
| Renal Failure Acute |
5.5% |
| Urinary Tract Infection |
5.5% |
| Pleural Effusion |
5.0% |
| Aplasia Pure Red Cell |
4.1% |
| Pneumonia |
4.1% |
| Urticaria |
4.1% |
| Weight Decreased |
4.1% |
| Myocardial Infarction |
3.6% |
| Nephrogenic Systemic Fibrosis |
3.6% |
| Osteonecrosis |
3.6% |
| Pain In Extremity |
3.6% |
| Pruritus |
3.6% |
| Renal Impairment |
3.6% |
| Sepsis |
3.6% |
| Therapeutic Response Decreased |
3.6% |
|
| Interacting |
| Graft Versus Host Disease |
27.3% |
| Anaemia |
13.6% |
| Hypertension |
13.6% |
| Thrombophlebitis |
13.6% |
| Prophylaxis |
9.1% |
| Diuretic Therapy |
4.5% |
| Dyspepsia |
4.5% |
| Hypertonic Bladder |
4.5% |
| Infection |
4.5% |
| Oedema |
4.5% |
|
| Toxic Epidermal Necrolysis |
60.0% |
| Rash |
20.0% |
| Urinary Tract Infection |
20.0% |
|
